Understand the source comparison
GLP-1 drugs vs DPP-4 inhibitors and other oral agents
Several large health-system datasets have compared GLP-1 RAs with DPP-4 inhibitors in people with type 2 diabetes and obesity. In these analyses, GLP-1 drug users showed about a 7% lower risk of obesity-related CANCs overall and an 8% lower risk of death from
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Several large health-system datasets have compared GLP-1 RAs with DPP-4 inhibitors in people with type 2 diabetes and obesity. In these analyses, GLP-1 drug users showed about a 7% lower risk of obesity-related CANCs overall and an 8% lower risk of death from any cause compared with matched patients taking DPP-4 inhibitors. The signal was particularly notable for colorectal CANCs, where some datasets reported approximately 16% fewer colon and 28% fewer rectal CANC cases among GLP-1 RA users.
- Similar findings have emerged when GLP-1 RAs are compared with some other oral agents. In many—but not all—cohorts, GLP-1 therapy appears to be a neutral or slightly favorable choice for obesity-related CANC risk, especially for tumors tied closely to excess adiposity and metabolic dysfunction.